

From: Nancy Trent/Pamela Wadler  
Trent & Company, Inc.  
594 Broadway – Suite 305  
New York, NY 10012  
212-966-0024  
[pam@trentandcompany.com](mailto:pam@trentandcompany.com)



For: US Specialty Formulations, LLC

**FOR IMMEDIATE RELEASE**

**RESEARCH DEMONSTRATES BENEFITS OF ORAL COVID-19 VACCINE**  
***QYNDR Vaccine Can Survive the Acidity of the Stomach and Reduces Viral Shedding***

**Allentown, PA** – Human clinical and pre-clinical data has shown that QYNDR, the oral-mucosal COVID vaccine particle, can survive stomach acidity and train the lymphatic system to recognize and respond to vaccine targets, in this case, COVID strains. As a mucosal vaccine, it also reduces the amount of viral 'shedding,' which is how an infected person spreads the live COVID-19 and many other respiratory viruses through nasal or oral secretions. This is possible because mucosal vaccines are delivered to the body via the oral route rather than injected into the bloodstream providing more "bang for the buck" in terms of protection.

Having an oral vaccine that can survive the acidity of the stomach and reduce viral shedding is a significant development for two reasons:

- 1.) Once the oral vaccine passes the stomach and into the intestines, it can deliver the antigen to the lymphatic system, which starts the body's process of anti-body generations, thus assisting in 'preventing' the virus from taking hold in the host. If the virus is able to overwhelm the immune system, then the effects/host should not suffer life-threatening trauma.
- 2.) A person who receives an injectable vaccine can continue to 'shed' the live virus as their body fights the internal infection. However, having an effective oral mucosal vaccine is believed to reduce the amount of shedding, leading to a reduction in outbreaks and the development of variants. This is a key point to global infectious disease and health departments attempting to halt the spread of disease.

There are several additional advantages to an oral mucosal-based vaccine over conventional injectable vaccines, such as fewer side effects, they can be self-administered and they do not need to be refrigerated. In fact, the QYNDR vaccine can withstand temperatures up to 143°F/60°C. This makes the vaccine easier to transport to remote locations since it does not require special handling, a perfect vaccine platform for any serious vaccination campaign.

Additionally, the QYNDR vaccine is 10ml of a drinkable liquid, much like water, without a taste or smell. [Dr. Kyle Flanigan](#), US Specialty Formulations (USSF) CEO and Co-founder, describes it as a

“swish and swallow” method. Future variations could contain a cocktail of several different vaccine particles. For example, it could include two (2) flu strains and six (6) COVID variants.

The proprietary technology available to USSF allows the company to tailor the platform – or vaccine targets – to a variety of different targets as USSF is looking for additional collaborations for just this purpose.

USSF completed the first stage of clinical trials and is proceeding into the second and third stages. Due to the magnitude of participants and global reach of these trials, USSF is seeking government and corporate funding. Succeeding in these trials will demonstrate the flexibility and power the oral QYNDR delivery technology provides, while the evidence concludes the vaccine may provide better overall protection than that of injectable vaccines – thus providing another tool in safeguarding domestic populations and internationally.

### **About USSF**

A minority-controlled business and manufacturer of sterile injectable, topical and specialty pharmaceuticals. It manufactures its own branded prescription products and provides clinical materials for investigational new drug applications, specialty formulations, adjuvants and fermentation and purification services requested by biotech companies.

This press release contains forward-looking statements within the meaning of the amended Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continues" or the negative of these terms or other comparable terminology. Not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond US Specialty Formulations LLC's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Except as required by law, US Specialty Formulations LLC disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on US Specialty Formulations LLC's current expectations and speak only as of the date of this press release.

###

**EDITOR'S NOTE: For more information about USSF and to arrange to speak with a company spokesperson, please contact Nancy Trent or Pamela Wadler at 212-966-0024 or [pam@trentandcompany.com](mailto:pam@trentandcompany.com).**